{
     "PMID": "28322979",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170905",
     "LR": "20170906",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "118",
     "DP": "2017 May 15",
     "TI": "3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus.",
     "PG": "157-166",
     "LID": "S0028-3908(17)30111-9 [pii] 10.1016/j.neuropharm.2017.03.019 [doi]",
     "AB": "The recreational drug of abuse, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier (BBB) integrity in rats through an early P2X7 receptor-mediated event which induces MMP-9 activity. Increased BBB permeability often causes plasma proteins and water to access cerebral tissue leading to vasogenic edema formation. The current study was performed to examine the effect of a single neurotoxic dose of MDMA (12.5 mg/kg, i.p.) on in vivo edema development associated with changes in the expression of the perivascular astrocytic water channel, AQP4, as well as in the expression of the tight-junction (TJ) protein, claudin-5 and Evans Blue dye extravasation in the hippocampus of adult male Dark Agouti rats. We also evaluated the ability of the MMP-9 inhibitor, SB-3CT (25 mg/kg, i.p.), to prevent these changes in order to validate the involvement of MMP-9 activation in MDMA-induced BBB disruption. The results show that MDMA produces edema of short duration temporally associated with changes in AQP4 expression and a reduction in claudin-5 expression, changes which are prevented by SB-3CT. In addition, MDMA induces a short-term increase in both tPA activity and expression, a serine-protease which is involved in BBB disruption and upregulation of MMP-9 expression. In conclusion, this study provides evidence enough to conclude that MDMA induces edema of short duration due to BBB disruption mediated by MMP-9 activation.",
     "CI": [
          "Copyright (c) 2017 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Perez-Hernandez, Mercedes",
          "Fernandez-Valle, Maria Encarnacion",
          "Rubio-Araiz, Ana",
          "Vidal, Rebeca",
          "Gutierrez-Lopez, Maria Dolores",
          "O'Shea, Esther",
          "Colado, Maria Isabel"
     ],
     "AU": [
          "Perez-Hernandez M",
          "Fernandez-Valle ME",
          "Rubio-Araiz A",
          "Vidal R",
          "Gutierrez-Lopez MD",
          "O'Shea E",
          "Colado MI"
     ],
     "AD": "Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. CAI Resonancia Magnetica Nuclear, Universidad Complutense, Paseo Juan XXIII, 28040 Madrid, Spain. Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. Electronic address: estheros@ucm.es. Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Pza. Ramon y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain. Electronic address: colado@ucm.es.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20170316",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Aqp4 protein, rat)",
          "0 (Aquaporin 4)",
          "0 (Claudin-5)",
          "0 (Enzyme Inhibitors)",
          "0 (Glial Fibrillary Acidic Protein)",
          "0 (Hallucinogens)",
          "0 (Heterocyclic Compounds, 1-Ring)",
          "0 (Low Density Lipoprotein Receptor-Related Protein-1)",
          "0 (SB 3CT compound)",
          "0 (Sulfones)",
          "9001-91-6 (Plasminogen)",
          "EC 3.4.24.35 (Matrix Metalloproteinase 9)",
          "KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Aquaporin 4/metabolism",
          "Blood-Brain Barrier/diagnostic imaging/drug effects/*physiopathology",
          "Brain Edema/*chemically induced/diagnostic imaging/pathology",
          "Claudin-5/metabolism",
          "Disease Models, Animal",
          "Enzyme Inhibitors/pharmacology",
          "Gene Expression Regulation/*drug effects",
          "Glial Fibrillary Acidic Protein/metabolism",
          "Hallucinogens/*toxicity",
          "Heterocyclic Compounds, 1-Ring/pharmacology",
          "Low Density Lipoprotein Receptor-Related Protein-1/metabolism",
          "Magnetic Resonance Imaging",
          "Male",
          "Matrix Metalloproteinase 9/*metabolism",
          "N-Methyl-3,4-methylenedioxyamphetamine/*toxicity",
          "Permeability/drug effects",
          "Plasminogen/metabolism",
          "Rats",
          "Sulfones/pharmacology",
          "Time Factors"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "AQP4",
          "Blood-brain barrier",
          "Edema",
          "Evans Blue dye (PubChem CID: 24832074)",
          "MDMA",
          "MDMA hydrochloride (PubChem CID: 71285)",
          "MMP-9",
          "SB-3CT",
          "SB-3CT (PubChem CID: 9883002)"
     ],
     "EDAT": "2017/03/23 06:00",
     "MHDA": "2017/09/07 06:00",
     "CRDT": [
          "2017/03/22 06:00"
     ],
     "PHST": [
          "2016/11/28 00:00 [received]",
          "2017/03/03 00:00 [revised]",
          "2017/03/15 00:00 [accepted]",
          "2017/03/23 06:00 [pubmed]",
          "2017/09/07 06:00 [medline]",
          "2017/03/22 06:00 [entrez]"
     ],
     "AID": [
          "S0028-3908(17)30111-9 [pii]",
          "10.1016/j.neuropharm.2017.03.019 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2017 May 15;118:157-166. doi: 10.1016/j.neuropharm.2017.03.019. Epub 2017 Mar 16.",
     "term": "hippocampus"
}